Clinical Trial Update: Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating irinotecan/cisplatin plus simvastatin in extensive-disease small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Irinotecan (Irinotecan)
• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED